Marty Chilberg
Long only, special situations, research analyst, healthcare

Sequenom: Deciphering The Business Model

As described in my first article, the noninvasive prenatal testing ("NIPT") market is evolving at a pace that has rarely been seen in healthcare. This nascent market provides a compelling opportunity for investors able to see it through a fog of uncertainty. Sequenom (NASDAQ:SQNM) has maintained market leadership, since their launch of MaterniT21 in October 2011. The investment challenge: decipher the financial reporting in order to recognize the value proposition.

Supplement the financials with performance metrics. The objectives of financial reporting include providing:

· Valuable information to existing and prospective investors, employees, and creditors.

· Content to determine the economic resources and obligations of an enterprise.

· Reports to assess the amounts, timing and uncertainties of prospective...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details